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Enhanced synaptic release of excitatory amino 
acid neurotransmitters may contribute to brain 
injury from hypoxia-ischemia (Meldrum, 1985; 
Simon et al., 1984). To examine this hypothesis in 
neonatal brain we tested MK-80I ,  a novel non- 
competitive N-methyl-D-aspartate  (NMDA)  re- 
ceptor antagonist, using an in vivo experimental 
model of hypoxic-ischemic forebrain injury (John- 
ston, 1983). To induce injury, seven day old rats 
were anesthetized with ether and the right carotid 
was ligated (N = 63), after which they recovered 
with the dam for 2 h. The pups were then placed 
in a warmed (37°C)  chamber and exposed to 8% 
oxygen balance nitrogen for 3 h, a procedure 
which resulted in hemispheric necrosis ipsilateral 
to the side of ligation. 
Effect of treatment was assessed using three 
MK-801 treatment protocols: administration of 1 
dose of MK-801 (1 m g / k g )  before hypoxia (N = 
10), a single dose during hypoxia (N = 18), or two 
doses, one before and another after 1.25 h of 
hypoxia (N = 9). In the second group, the timing 
of treatment was varied to determine if there was 
a critical time threshold for efficacy: a single dose 
was given after 1.25 h (N = 5), 1.5 h (N = 6) or 2.5 
h (N = 7). Pups received one or two intra- 
peritoneal injections of M K  = 801 (N = 37) or 
phosphate buffered saline (N = 26); a group of 
untreated litter-mates served as additional con- 
trols (N = 5). Pups were sacrificed 5 days after 
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hypoxia, and right and left hemisphere weight 
disparities were compared as percent reductions 
( [ ( R -  L) /L]  × 100) by condition using Student's 
t-test for paired values. During this phase of rapid 
brain growth, reduction in hemisphere weight can 
be used as an indicator of injury more readily than 
in adults. 
There was prominent neuronal loss in hippo- 
campus, cortex and caudate-putamen of saline- 
treated ligates. MK-801 administration reduced 
hypoxic-ischemic neuronal damage both grossly 
and microscopically as compared the opposite side. 
When compared to saline treated hypoxic-ischemic 
controls, two MK-801 injections were most effec- 
tive in reducing cerebral hemisphere damage 
(saline treated, - 11.2 + 2 vs. - 1.7 _+ 1.3% P < 
0.001). Figure 1 compared littermate pups treated 
with saline or MK-801 at the onset and 1.25 h into 
hypoxia, to normal controls. A single MK-801 
dose at the onset ( - 3 . 7  _+ 6.9 P < 0.05) or after 
1.25 h of hypoxia ( - 3 . 1  _+ 3.2% P < 0.01) was 
similarly effective while single injections at 1.5 or 
2.5 h into hypoxia were least effective. MK-801 
eliminated moderate to severe injury ( >  10% re- 
duction in hemisphere weight) in protocols with 
two doses or a single dose at 1.25 h. The incidence 
of hemispheric necrosis in groups given a pre-hy- 
poxia dose or treated at 1.5 h with MK-801 was 
reduced to 20 and 33%, respectively. The inci- 
dence of severe necrosis in pups that received 
MK-801 after 2.5 h of hypoxia (57%) was no 
different from saline treated controls. Thus, proto- 
cols in which MK-801 was administered before 
1.25 h into hypoxia were most effective in limiting 
neuronal damage. The data suggest that there is a 
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Fig. 1. Comparison of right and left hemisphere weights in animals killed on day 12. Unilateral hypoxic-ischemic forebrain injury was 
produced by right carotid artery ligation and subsequent exposure to 8% oxygen (balance nitrogen) for a 3 h period in 7 day old rat 
pups. Controls were untreated pups not exposed to hypoxia-ischemia. MK-801 and hypoxia-ischemia groups were exposed to 
hypoxic-ischemic conditions and were given i.p. injections of either MK-801 (1 mg/kg) or an equivalent volum e of saline at the onset 
and 1.25 h into hypoxia. Data represent only those litters containing double MK-801 treated pups and were expressed as 
means_+ S.E.M. Boxes represent S,E.M. * P < 0.05; ~ P < 0.01. 
cr i t ical  t ime threshold  for drug intervent ion.  
MK-801 may  pro tec t  the immatu re  b ra in  f rom 
hypox ia - i schemia  by  b ind ing  to phencyc l id ine- l ike  
sites associa ted  with the N M D A  recep tor  ope ra t ed  
channel  complexes  ( W o n g  et al., 1986). The  results  
are consis tent  with our  previous  observa t ions  that  
hypox ia - i schemia  acute ly  d i s rup ts  g lu tamate  b ind-  
ing sites in regions (e.g. s t r i a tum and h ippocam-  
pus)  suscept ib le  to injury in the mode l  (Si lverstein 
et al., in press). In add i t iona l  exper iments  we 
found that  MK-801 b locks  the necrosis  p roduced  
by direct  in ject ion of N M D A  into  the 7 day  old 
s t r ia tum. The  drug  may  b lock  lethal  ca t ion  ent ry  
into neurons  a n d / o r  d iminish  pos t - i schemia  neu- 
ronal  hyperexci tabi l i ty .  I t  is no tewor thy  that  
b l o c k a d e  of N M D A  receptors  a lone with in- 
t r ace rebroven t r i cu la r  inject ion of 2 -aminophos-  
p h o n o h e p t a n o i c  acid  (APH)  failed to pro tec t  from 
injury  in the mode l  (Silverstein and Johns ton ,  
unpubl ished) .  The  da ta  suggest that  N M D A  re- 
cep to r  channel  ac t iva t ion  plays  an impor t an t  role 
in the pa thogenes is  of hypoxic- i schemic  bra in  in- 
jury .  N M D A  channel  b lockade  might  p rov ide  a 
therapeut ic  s t rategy for hypoxic  d isorders  of the 
fetal and  pos tna t a l  brain.  
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